Linus Alexander Völker

Clinical Nephrologist @ University Hospital of Cologne & avid birder. Tweets are my own.

[Linus Alexander Völker @LinusAlexanderV]

Proud to share another collab of German and Austrian #TTP registries. Important implication for managing acute #TTP. Revisiting clinical response and refractoriness in immune thrombotic thrombocytopenic purpura https://t.co/HrSw5uN478

[Roman-Ulrich Müller @MuellerRom]

I usually think twice before posting preprints. But this time it’s different.
MEDA-PKD is the essence of our work over more than a decade — and, to me, one of the most meaningful contributions I’ve been able to make to biomedical research.
🧵

[Linus Alexander Völker @LinusAlexanderV]

Refractory #iTTP in the #caplacizumab era is exceedingly rare and oftentimes related to secondary factors: Revisiting Clinical Response and Refractoriness in Immune Thrombotic Thrombocytopenic Purpura https://t.co/HrSw5uN478

[AmericanJournalofHematology @AjHematology]

Large multicenter retrospective analysis indicating that the incorporation of caplacizumab into treatment of immune TTP in the ICU improves the ICU survival. Overall ICU survival was high.
https://t.co/8ECi2dDxST
@Ralph_Wendt @LinusAlexanderV @oncologne @UKKoeln

[Roman-Ulrich Müller @MuellerRom]

Obtaining a thorough family history is so important in kidney disease....but often more difficult than expected in clinical practice...

10 tips on how to take a proper family history in CKD patient care url: https://t.co/T3zE4tJ4UU

[Roman-Ulrich Müller @MuellerRom]

1/
🚨 Big news from our Genes&Kidney Working Group at the @ERAkidney
We just released a consensus statement in Nephrology Dialysis Transplantation aiming to bring us closer to precision medicine in CKD. 🧬🩺
🧵 THREAD 👇

[Linus Alexander Völker @LinusAlexanderV]

@Basalus Great overview! But don’t forget thrombotic thrombocytopenic purpura, particularly in young females! #TTP

[Linus Alexander Völker @LinusAlexanderV]

🚨 The Capla1000+ project published!
Early use of caplacizumab significantly reduces mortality and time to response.
💥 3-mo survival: 98.5% vs. 94% (controls)
🩸 Bleeding in 2.4%, mostly elderly
💡 Age key mortality factor
🔗https://t.co/1y7Fic2TC3
#TTP #Caplacizumab

[Linus Alexander Völker @LinusAlexanderV]

@alex_epi_tria @WilliamAird4 They certainly are encouraging. There might also be a role for advanced anti-CD20-therapies but clearly there is not enough data on refractory TTP.

[William Aird @WilliamAird4]

1/6

TPE-FREE MANAGEMENT OF IMMUNE TTP (iTTP)

Retrospective study from Austria and Germany

ADAMTS13 activity at baseline <10% in all patients

Treatment group (TPE-free): 42 acute iTTP episodes in 41 patients received TPE-free management with caplacizumab + steroids +/- Ritux

[Rafeeque @rafeequemavoor]

Free scientific illustrations for biologists! 😍

@NIH has released a library of 500+ free scientific illustrations to create figures, presentations, and illustrations!

all freely available in the public domain.

Retweet and spread the message!
https://t.co/p1bD1kxO7H

[Joel M. Topf, MD FACP @kidney_boy]

Made it to the LBCT session
And it is a hyponatremia trial!

#KidneyWk

[flora peyvandi @flora_peyvandi]

Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange. This is a real change in treatment of our iTTP patients! Congratulations to the authors for this nice paper https://t.co/u4AJ97f1Ex

[Linus Alexander Völker @LinusAlexanderV]

iTTP treatment w/o plasma exchange -final print version now out! Exploring novel treatment paradigms and alleviating treatment burden with the support of great international colleagues!
https://t.co/fOtpOlGwEP

[Linus Alexander Völker @LinusAlexanderV]

What’s new in nephrotic syndrome? An Updated Comprehensive Review on Diseases Associated with Nephrotic Syndromes ⁦- thanks to all coauthors and great collab w/@Ralph_Wendt⁩ https://t.co/lyIECs3B27

[Victor Suárez @vsuarez_md]

Wie übernehmen wir Patienten unter laufender CPR im Schockraum? Wie lagern wir um, wechseln das Device, kommunizieren etc? Solche (+ viele andere) Situationen üben wir in unseren interdisziplinären SR-Trainings im Schwerpunkt KAN der Uniklinik Köln #ukk

[Saarang Deshpande, MD @SR_DeshpandeMD]

🧵Thread on frontline caplacizumab and plasma exchange in TTP🚨

With advancing care for immune thrombotic thrombocytopenic purpura (iTTP), let’s discuss frontline caplacizumab (capla) and the future for therapeutic plasma exchange (TPE) ⤵️

#hemetwitter #TTP #caplacizumab
1/22

[Linus Alexander Völker @LinusAlexanderV]

@SR_DeshpandeMD @HTRSFellows @HTRStoday @isth @AaronGoodman33 @survivingTTP Thank you for engaging with our work! Nice thread! Some points are certainly up to discussion (cost effectiveness, mortality, risk stratification). At this point I still also have to strongly advise against the indiscriminate use of TPE-free treatment. We hopefully get there!

[Linus Alexander Völker @LinusAlexanderV]

Our comment on Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura | New England Journal of Medicine https://t.co/o4HC13sr53
@Ralph_Wendt and Paul Brinkkötter